<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02518932</url>
  </required_header>
  <id_info>
    <org_study_id>VTC-G15</org_study_id>
    <nct_id>NCT02518932</nct_id>
  </id_info>
  <brief_title>The Effect of VTC-G15 (a Pentapeptide Cleavage Product og GLP-1) on Whole Body Glucose Metabolism in Man</brief_title>
  <acronym>LVKGR</acronym>
  <official_title>The Effect of VTC-G15 (a Pentapeptide Cleavage Product og GLP-1) on Whole Body Glucose Metabolism in Man</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elahi, Dariush, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICON plc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Elahi, Dariush, PhD</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To asses the modulating properties of the cleaved pentapeptide product of GLP-1 amide.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators have previously demonstrated that infusion of the pentapeptide during
      hyperglycemic clamps in dogs significantly increases the glucose infusion rate necessary to
      maintain stable hyperglycemia without any significant differences in insulin or glucagon
      secretion. The present study's aim is to examine whether this also occurs in humans. It may
      be necessary to examine a dose response curve. Specifically, in twenty healthy volunteers
      glucose infusion rate during the peptide infusion will be compared to the glucose infusion
      rate during saline administration during a 4 hour hyperglycemic clamp, in a cross over
      design(mg/kg/min).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The effect of VTC-G15 on whole body glucose metabolism in man will be assessed by comparison of amont of glucose infusion during the peptide infusion compared to amount of infusion during placebo infusion (saline) mg/kg/min.</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>THe effect of VTC-G15(A pentapeptide cleavage product of GLP-1) on whole body glucose metabolism in man.</measure>
    <time_frame>one year</time_frame>
    <description>changes in insulin or glucagon release.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Drug GLP-1 (32-36) Amide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To examine insulinomemtic of the last 5 amino acids of GLP-1 from 60-180 min during a 4 hour hyperglycemic clamp</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>To examine the effect of saline on glucose uptake</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Last 5 amino acids of GLP-1</intervention_name>
    <description>To examine insulinomimetic properties of LVKGR</description>
    <arm_group_label>Drug GLP-1 (32-36) Amide</arm_group_label>
    <other_name>VTC-G15; LVKGR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo saline</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI 18.5-25;

          -  33-38

        Exclusion Criteria:

          -  T2D

          -  T1D

          -  Hypoglycemic agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dariush Elahi, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICON plc, 8307 Gault Lane, San Antonio TX 78209</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dariush E;ahi, PhD</last_name>
    <phone>210-283-4520</phone>
    <email>dariush.elahi@iconplc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dennis A Ruff, MD</last_name>
    <phone>210-283-4572</phone>
    <email>dennis.ruff@iconplc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ICON PLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita Flusche</last_name>
      <phone>210-283-4123</phone>
      <email>Rita.flusche@iconplc.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2015</study_first_submitted>
  <study_first_submitted_qc>August 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2015</study_first_posted>
  <last_update_submitted>August 7, 2015</last_update_submitted>
  <last_update_submitted_qc>August 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
    <mesh_term>Glucagon</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

